← All trials
NCT02421887
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2015
- Primary completion
- Dec 1, 2018
- Completion date
- Dec 1, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 190
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Yale UniversityLead sponsor
- University of North Carolina at Chapel HillOverall official - principal investigator
- Yale UniversityReponsible party - principal investigator
- Augusta UniversityStudy director
- University of California, San FranciscoStudy director
- University of OklahomaStudy director
- University of PennsylvaniaStudy director
- Yale UniversityStudy director
- University of Colorado, DenverStudy chair
- Augusta UniversityCollaborator
- University of California, San FranciscoCollaborator
- University of OklahomaCollaborator
- University of PennsylvaniaCollaborator
- University of North Carolina at Chapel HillCollaborator
- National Institutes of Health (NIH)Study director
- Pennsylvania State UniversityStudy director
- Pennsylvania State UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.